N-Benzyl-N-(pyrrolidin-3-yl)carboxamides as a new class of selective dual serotonin/noradrenaline reuptake inhibitors

Bioorganic and Medicinal Chemistry Letters

Volumn 18, Issue 15, 2008, Pages 4308-4311

  Wakenhut, Florian ^a   Fish, Paul V ^a   Fray, M Jonathan ^a   Gurrell, Ian ^a   Mills, James E ^a   Stobie, Alan ^a   Whitlock, Gavin A ^a  

^a PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

Author keywords

CYP2D6 inhibition; Lipophilicity; Metabolic profile; Metabolic stability; N benzyl N (pyrrolidin 3 yl)carboxamides; Noradrenaline reuptake; Serotonin reuptake; SNRI

Indexed keywords

N BENZYL N (PYRROLIDIN 3 YL)CARBOXAMIDE; SEROTONIN; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; UNCLASSIFIED DRUG;

ARTICLE; CENTRAL NERVOUS SYSTEM; DRUG STRUCTURE; DRUG SYNTHESIS; LIPOPHILICITY; PHYSICAL CHEMISTRY; STRUCTURE ACTIVITY RELATION;

AMIDES; ANIMALS; CENTRAL NERVOUS SYSTEM; COMBINATORIAL CHEMISTRY TECHNIQUES; CYTOCHROME P-450 CYP2D6; DOGS; DOPAMINE UPTAKE INHIBITORS; DRUG DESIGN; HEPATOCYTES; HUMANS; INHIBITORY CONCENTRATION 50; MICROSOMES, LIVER; MOLECULAR CONFORMATION; NOREPINEPHRINE; PYRROLIDINES; SEROTONIN; SEROTONIN UPTAKE INHIBITORS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 47749105256     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2008.06.078     Document Type: Article

References (21)

1. Jann M.W., and Slade J.H. Pharmacotherapy 11 (2007) 1571
2. Montgomery S. Int. J. Psychol. Clin. Pract. 10 Suppl. 2 (2006) 5
3. Jackson S. Curr. Med. Res. Opin. 21 (2005) 1669
4. Wernicke J.F., Iyengar S., and Ferrer-Garcia M.D. Curr. Drug Ther. 2 (2007) 161
5. Bauer M., Moeller H.-J., and Schneider E. Expert Opin. Pharmacother. 7 (2006) 421
6. Kajdasz D.K., Iyengar S., and Desaiah D. Clin. Ther. 29 (2007) 2536
7. Thor K.B., Kirby M., and Viktrup L. Int. J. Clin. Pract. 61 (2007) 1349
8. Mariappan P., Alhasso A., Ballantyne Z., Grant A., and N'Dow J. Eur. Urol. 51 (2007) 67
9. Steers W.D., Herschorn S., Kreder K.J., Moore K., Strohbehn K., Yalcin I., and Bump R.C. BJU Int. 100 (2007) 337
10. Fray M.J., Bish G., Brown A.D., Fish P.V., Stobie A., Wakenhut F., and Whitlock G.A. Bioorg. Med. Chem. Lett. 16 (2006) 4345
11. Fray M.J., Bish G., Fish P.V., Stobie A., Wakenhut F., and Whitlock G.A. Bioorg. Med. Chem. Lett. 16 (2006) 4349
12. Fish P.V., Fray M.J., Stobie A., Wakenhut F., and Whitlock G.A. Bioorg. Med. Chem. Lett. 17 (2007) 2022
13. Whitlock G.A., Blagg J., and Fish P.V. Bioorg. Med. Chem. Lett. 18 (2008) 596
14. Fish P.V., Deur C., Gan X., Greene K., Hoople D., MacKenny M., Para K.S., Reeves K., Ryckmans T., Stiff C., Stobie A., Wakenhut F., and Whitlock G.A. Bioorg. Med. Chem. Lett. 18 (2008) 2562
15. Lee J.T., Kroemer H.K., Silberstein D.J., Funck-Brentano C., Lineberry M.D., Wood A.J., Roden D.M., and Woosley R.L. New Engl. J. Med. 322 (1990) 100
16. 50 values, that is, concentration required to inhibit the specific uptake of radiolabelled substrate into the cells by 50% relative to maximum (vehicle only) over a 10-point dose-response range.
17. Mahar Doan K.M., Humphreys J.E., Webster L.O., Wring S.A., Shampine L.J., Serabjit-Singh C.J., Adkison K.K., and Polli J.W. J. Pharm. Exp. Ther. 303 (2002) 1029
18. Leeson P.D., and Springthorpe B. Nat. Rev. Drug Discov. 6 (2007) 881
19. -1) for apical to basolateral (AB) and basolateral to apical (BA) directions. See: Van de Waterbeemd, H.; Smith, D. A.; Beaumont, K.; Walker, D. K. J. Med. Chem. 2001, 44, 1313 and references therein.
20. Fermini B., and Fossa A.A. Nat. Rev. Drug Discov. 2 (2003) 439
21. Keating M.T., and Sanguinetti M.C. Cell 104 (2001) 569